Nat. Volatiles & Essent. Oils, 2022; 9(1): 2001-2010

NVEO
Natural Volatiles &
Essential Oils

Absue- Deterrant Formulation Bcs Class -1 Drug Involving Against The Abuse And Misuse Of Opioid Analgesics: A Review

[1]Varinder Kumar* , [2] Dr. Amul Mishra

[1*]Faculty of Pharmacy, BN Institute of Pharmaceutical Sciences, BN University, Udaipur, Rajasthan, India.

[2]Associate Professor & Head department of Pharmaceutics, BN Institute of Pharmaceutical Sciences, Faculty of Pharmacy, BN University, Udaipur, Rajasthan, India.

Abstract

Opioid addiction has exploded in the US. It costs the health care system and society money. To balance the demands of chronic pain patients who may benefit from opioid treatment, prescription opioid misuse and addiction must be reduced. Prevent prescription opioid usage and abuse by employing an abuse-deterrent formulation (ADF). Because of their unique properties, these opioids are less appealing to abuse. The FDA issued final guidelines for ADF opioid development in 2015, recommending that new opioid formulations be investigated for abuse-deterrent properties. Industry received this direction. The increased use of opioid pain medications has led to increased misuse and abuse. The pharmaceutical industry has stepped up research and development of abuse-deterrent formulations. Various technologies are being investigated to achieve pain treatment while reducing the risk of misuse and abuse. The abuse-deterrent compositions of some of these goods, as well as the current regulatory situation in the United States, will be examined. ADF opioid preclinical and clinical investigations are going quickly. Several tests are required to determine an ADF opioid's abuse-deterrent properties. Medical professionals will gain insight into the development of extended-release ADF opioids and their importance in pain management. Misuse-deterrent formulations (ADFs) are intended to decrease prescription drug abuse while ensuring that people who actually need them have access to life-saving treatments.

Keywords: FDA, Opioids Miss-use, ADF, Prescription Opiods Absue

1.1 Introduction

Around 116 million Americans have chronic nonmalignant pain, a silent epidemic. So patients go to the doctor for the most common reasons. Each year, medical costs and lost productivity total $635 billion[1]. The physiology of chronic pain is still unknown, but it has been linked to several mental health disorders, including inability to eat or sleep and despair. Using a multimodal treatment strategy is critical in treating chronic pain patients. Acute and chronic pain syndromes have many facets that need to be addressed by health care providers. Non-pharmacological interventions have been shown to reduce overall pain complaints[2-4]. Massage, physical and occupational therapy, biofeedback, guided imagery,

and CBT are some examples[5]. In some cases, interventions like nerve blocks, TENS, and injectable medicines are used. However, non-opioid and opioid analgesics are frequently used in therapy to manage pain. Misuse of prescription opioid analgesics has reached epidemic proportions, endangering public health. If nonpharmacological and nonopioid treatments fail to relieve pain, opioid therapy may be required[6-8]. Opioid prescribers must weigh the risks and benefits of their decisions. Prescription painkillers can be abused by snorting, injecting, inhaling, or chewing them. Nonoral manipulations of immediate and protracted opioids are meant to make the active component more easily misused and release the opioid faster (e.g. nose inhalation, intravenous injection solution) (known as dose dumping)[9,10]. Nonoral opioid delivery has more severe medical effects. According to study, tampering with opioid prescriptions can lead to higher medical costs than abuse alone. It's part of a complicated approach to prevent opiate overuse and abuse while keeping opioids available for those in need[11]. Abuse-deterrent opioids include opioid agonist/antagonist combinations, physical and pharmacological barriers, and other properties. Contrary to the FDA's stated intention, ADFs will not completely prevent abuse of opioid analgesics. This review will describe the regulatory issues surrounding ADF opioid development and clarify abuse-deterrent claims. This data will help clinicians evaluate the evidence on opioid analgesics' abuse-deterrent properties[12-15]. Clinicians and other healthcare professionals decide which patients receive ADF opioids and which receive standard opioids. This data is vital in developing clinical guidelines and policy recommendations for ADF use. Clinical guidelines, state regulations, and insurance mandates have relegated long-acting opioids to a secondary or tertiary role in treatment.

There are few studies on ADF use. Opioids were the only ADFs available in the US in February 2021. Prescriptions for opioid analgesics with extended-release have fallen dramatically since 2010, and ADFs now account for only 2% of those. Extended-release oxycodone formulations like OxyContin® and Xtampza® dominated the ADF market, accounting for 78% of sales. When OxyContin 80 mg was reformulated in 2010, 14% of users stopped taking opioids and 40% switched to another opioid. Another early extended-release ADF, EMBEDA® (morphine sulphate and naltrexone hydrochloride extended-release), was discontinued in 2019[16,17,18]. It's critical to look into the use of ADFs in clinical practise, especially the reasons for prescribing them. A few studies examined prescribers' perceptions of anti-abuse properties. In 2010, physicians who were board-certified in pain medicine and had a high volume of opioid prescriptions were more likely to prescribe tamper-resistant opioids. A 2014 survey found that half of those polled thought ADFs were "less addictive" than standard formulations. Before the current ADFs, people who use drugs illegally were polled about their views on tamper-deterrent features. To our knowledge, no recent survey has examined ADF prescribing reasons [19-20].

After a decade on the market and a shift in opioid prescribing standards, understanding ADF use is critical. ADFs are generally more expensive than standard formulations, both in retail and healthcare. In some states, third-party payers must pay ADFs at the same rate as conventional medications [21]. These and other factors affect ADF opioid patients. ADFs are evaluated in real-world data outside of clinical treatment based on patient selection. Observational studies comparing ADFs to non-ADFs may be biassed or "confounded by indication" if these newer drugs are given to patients at higher risk of opioid abuse or overdose. As a result, clinical decision-making for ADF opioids must be better understood [22-24].

2.1 Overview of Prescription drug Abuse Epidemic

Controlled substances can successfully treat a wide range of diseases when taken as prescribed by a qualified physician. The diversion, misuse, and abuse of controlled substances have increased dramatically in the United States over the last decade[25].

2.2 Administration and Genetical Assessment

Researchers have linked two primary dopaminergic pathways in the brain, the mesolimbic and mesocortical, to addiction[26]. The amygdala, hippocampus, and nucleus accumbens are all part of complex circuits that include the mesolimbic and ventral tegmental pathways (Fig. 1). The mesocortical route targets the prefrontal cortex. Dopaminergic neuron activation is essential for rats to learn to press a lever to deliver an electric pulse to the route. Some rats may starve themselves to keep getting VTA stimulation. Together, mesocorticolimbic dopamine (DA) circuitry is engaged in the rewarding effects of a stimuli. Dopaminergic transmission in this system responds to rewards as well as indicators that predict whether or not a reward will arrive[27,28].



Fig 1: Mesocorticolimbic system is usually linked in SUDs occurrences. The coloured (various grey colours in the print version) lines reflect diminished functional connectivity across numerous nodes of a mesocorticolimbic system in cocaine-dependent people. Addicts' "stop" and "go" responses to drug use may be mediated by two different mesocorticolimbic circuits [29,30].

2.3 Dosage method and opioid abuse

Prescription drug abuse has become a huge public health issue. Except for marijuana, adolescents and young adults use the most illicit drugs. Contrary to popular belief, some widely given drugs can be abused, misused, or diverted for non-medical purposes. Some youths use prescription drugs to have fun (e.g. become "high"), relieve stress or worry, or improve academic performance[31]. Drugs can be obtained through friends or family, doctors' prescriptions, drug dealers, or the internet. Prescription drug use among young people in the UK is rarely examined nationally, but studies indicate it is rising.

2.4 Increase use of drug during Pandemic

In the face of such a dire situation, everyone, including drug users, must work together. A person's personality may help them survive a quarantine period better than others. Quarantine can be a painful ordeal for substance addicts[32]. Movement and drug availability restrictions can influence drug users' behaviour. People have been escaping quarantine in search of drugs, according to reports in Italy. The stress of quarantine may have exacerbated some people's mental health issues. Addictions can harm one's mental and physical health. Anxiety and stress are the biggest threats to public mental health. However, new and stricter regulations are projected to increase alcohol and drug abuse due to their impact on many people's lifestyles and well-being[33]. Suicidal thoughts and actions, sadness, and self-harming behaviours were anticipated. As a result, future drug addicts will have more difficulty accessing narcotics. A result of the current crisis, illegal drug trafficking is now only possible online via specialised websites and private couriers. As a result, internet cannabis sales increased in the first three months of 2020. The authors suggest postal police limitations should be tightened to halt the problem's expansion. Opioids, new synthetic opioids[34,35], or new benzodiazepines, which can be consumed in solitude and have a relaxing effect, are expected to become more popular among recreational drug users. Concerns have been expressed concerning the availability of legal alternatives like methadone and buprenorphine to manage withdrawal symptoms, reduce drug cravings, and prevent opiate overdoses[36]. As a result, there may be more isolated overdoses and fewer naloxone administrations, perhaps leading to more deaths. Due to the pandemic, face-to-face meetings may be suspended or reduced. We believe that medication treatment services should be available without interruption, including replacement therapies and other vital drugs, as well as backup measures in case of shortages[37,38]. Before the epidemic, opiate addicts were treated with daily doses of methadone administered under close supervision. Currently, this may not be possible. Patients in opioid addiction treatment who are stable enough should acquire enough methadone or buprenorphine for several days[39]. Despite recent advances, opioids are still used to treat severe intractable pain. Since 2002, prescription opioid overdose deaths and addiction treatment admissions have skyrocketed. Fig. 2 In the year ending July 2019, there were 66,9750 drug overdose deaths in the US, 58 percent of which were opioids (excluding heroin or methadone). The number of drug overdose deaths (58,545) and the percentage of those deaths containing opioids are both up significantly over last year (47.0 percent)[40]. Over a third of the expense is attributed to increased health care and drug treatment costs, with the rest going to the government.



Fig 2: Drug overdose death 2002-2020

3. Physical & Mechanical Barrier

These ADFs keep the active component out of reach by enforcing a physical barrier. Abusing excess amounts or tablets would still occur, but would be more difficult and time consuming. This physical barrier prevents chewing, grinding, crushing, and other extraction procedures. This can be done using an external shell or a drug delivery system[41,42].

3.1 Oxycodone Extended Release (Oxycontin, Purdue Pharma)

Oxycodone, a single agonist opioid, provides analgesia. Like mixed or non-opioid analgesics, pure opioid agonist analgesics have no maximum dose; the analgesic effectiveness ceiling is only imposed by side effects, which can include somnolence and respiratory depression. OxyContin's oxycodone hydrochloride ER tablet composition is one (HCl). It is safe and effective for treating chronic pain that requires daily, round-the-clock opioid prescription and other options are insufficient[43]. When taken as directed, OxyContin releases oxycodone over a 12-hour period (tablet swallowed whole). Causing the original OxyContin to break or chew freed the oxycodone from the extended-release matrix. Thereafter, it was crushed and dissolved for intravenous injection, then crushed and dissolved for IV injection. Epidemiological studies frequently noted non-oral abuse of the original OxyContin formulation[44]. According to the NAVIPPRO Treatment Centers PMR research, injection (55.7%) and insufflation (54.9%) were the most common methods of abuse for OxyContin in 2010. Two years later, the medicine was

reformulated (34.8percent). For easy consumption or administration through gastrointestinal tubes, patients and caregivers were concerned about accidental exposure and unexpected outcomes.

3.2 Oxymorphone (marketed as Opana ER)

Opana ER (oxymorphone hydrochloride extended-release tablets) is an opioid analgesic used to treat moderate-to-severe pain that requires a 24-hour supply. Endo Pharmaceuticals sells it as a reformulation of the original drug, with physicochemical properties designed to prevent snorting and injecting abuse[45]. The FDA found that the medicine did not meet the threshold for being declared abuse-deterrent and consequently rejected Endo's request. Endo asked the authorities to confirm that the original Opana ER was withdrawn from the market in 2012 due to safety concerns (which would result in withdrawing generic products referencing original Opana ER from the market). Endo Pharmaceuticals is the sole provider of Oxymorphone (Opana and Opana ER). Opana ER was discontinued in 2017 and is no longer accessible in the US. Many laboratories make Oxymorphone IR and Oxymorphone ER under the generic names Oxymorphone and Oxymorphone. Oxymorphone is also an injectable for inpatient use. I.V., I.M., or S. An extended release (ER) modified-release dosage form is commonly used to alter the pharmacokinetics of the drug[46].

Future Adoption in Abuse Deterrent Pharmaceutical Market 2019-2035

Although the healthcare system relies on individuals taking their medication as recommended, 18 million people misused prescription medications in 2017. Environ 2 million Americans had initially misused prescription opioids, according to the National Survey on Drug Use and Health. An estimated 1 million people abused prescription stimulants, 1.5 million used tranquillizers, and 270,000 used sedatives for the first time[47]. Due to the frequency of prescription drug addiction, pharmaceutical companies have had to develop a range of methods to reduce usage. ADFs for medicines that are most prone to be misused are among the most common ways to avoid addiction. Drug formulations designed to avoid the abuse of an active pharmacological agent have been identified as an alternative to lowering recreational and off-prescription drug use and the consequences that follow[48]. The research "Abuse Deterrent Formulation Technologies Market, 2019-2035" examines industry players who supply pharmaceutical companies with abuse deterrent formulation technologies. These profiles offer detailed descriptions of proprietary technology and a company overview if financial data is provided. The latest news for each player includes notable achievements, partnerships, and future growth initiatives. From 2000 to 2019, a complete examination of abuse deterrent formulation patents submitted or awarded. The report's main purpose was to identify the market's key growth drivers and forecast its future size. We've forecasted the market's expected evolution from 2019 to 2035 based on projected licencing and contract agreements between pharmaceutical and technology companies[49-50].

Conclusion

The study indicated that ADF prescribing is driven less by patient misuse concerns and more by limiting family diversion and establishing a population supply. Opioid prescribing psychology has received little

attention. To better comprehend the patient, prescriber, and environment components, we may incorporate community-level overdose data, news media, and public and professional sentiment measures.

References

1. Manchikanti L, Helm Ii S, Fellows B, Janata JW, Pampati V, Grider JS, et al. Opioid epidemic in the United States. Pain Physician. 2012;15:ES9–ES38

2. Hall AJ, Logan JE, Toblin RL, Kaplan JA, Kraner JC, Bixler D, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA. 2008;300:2613–20. doi: 10.1001/jama.2008.802.

3. Manchikanti L, Singh A. Therapeutic opioids: a ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician. 2008;11:S63–88.

4. Belouin SJ, Reuter N, Borders-Hemphill V, Mehta H. Prescribing trends for opioids, benzodiazepines, amphetamines, and barbiturates from 1998–2007. Available at http://nac.samhsa.gov/DTAB/Presentations/Aug08/SeanBelouinDTAB0808.ppt.

5. Denisco RA, Chandler RK, Compton WM. Addressing the intersecting problems of opioid misuse and chronic pain treatment. Exp Clin Psychopharmacol. 2008;16:417–28. doi: 10.1037/a0013636.

6. Cicero TJ, Inciardi JA, Munoz A. Trends in abuse of oxycontin and other opioid analgesics in the United States: 2002–2004. J Pain. 2005;6:662–72. doi: 10.1016/j.jpain.2005.05.004.

7. Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend. 2006;81:103–7. doi: 10.1016/j.drugalcdep.2005.05.009.

8. Substance Abuse and Mental Health Services Administration, NSDUH Series H-41 (2011) Results from the 2010 National Survey on Drug Use and Health: Summary of National Findings

9. Anonymous (2011) Epidemic: responding to America's prescription drug abuse crisis. Available at http://www.whitehouse.gov/sites/default/files/ondcp/issues-content/prescription-drugs/rx_abuse_plan.pdf.

10. Farre M, Cami J. Pharmacokinetic considerations in abuse liability evaluation. Br J Addict. 1991;86:1601–6. doi: 10.1111/j.1360-0443.1991.tb01754.x.

11. Webster LR, Bath B, Medve RA. Opioid formulations in development designed to curtail abuse: who is the target? Expert Opin Investig Drugs. 2009;18:255–63. doi: 10.1517/13543780902751622.

12. Katz N. Abuse-deterrent opioid formulations: are they a pipe dream? Curr Rheumatol Rep. 2008;10:11–8. doi: 10.1007/s11926-008-0003-z.

13. U.S. Food Drug and Administration, Center for Drug Evaluation and Research (2012) Code of Federal Regulations Title 21, 21CFR320.25

14. U.S. Food Drug and Administration, Center for Drug Evaluation and Research (2012) Code of Federal Regulations Title 21, 21CFR211

15. Passik SD, Hays L, Eisner N, Kirsh KL. Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. J Pain Palliat Care Pharmacother. 2006;20:5–13. doi: 10.1080/J354v20n02_03

16. Katz N, Dart RC, Bailey E, Trudeau J, Osgood E, Paillard F. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse. 2011;37:205–17. doi: 10.3109/00952990.2011.56962

17. Baum C, Hsu JP, Nelson RC. The impact of the addition of naloxone on the use and abuse of pentazocine. Public Health Rep. 1987;102:426–9.

18. Lahmeyer HW, Craig RJ. Pentazocine–naloxone: another "addiction-proof" drug of abuse. Int J Addict. 1987;22:1163–6. doi: 10.3109/10826088709027478

19. Mastropietro DJ, Omidian H (2012) Current approaches in tamper-resistant and abuse-deterrent formulations. Drug Dev Ind Pharm

20. Anonymous (2012) Oxycontin (oxycodone extended-release). Availableat http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022272s011lbl.pdf.

21. Hays L, Kirsh KL, Passik SD. Seeking drug treatment for OxyContin abuse: a chart review of consecutive admissions to a substance abuse treatment facility in Kentucky. J Natl Compr Canc Netw. 2003;1:423–8

22. Carise D, Dugosh KL, McLellan AT, Camilleri A, Woody GE, Lynch KG. Prescription OxyContin abuse among patients entering addiction treatment. Am J Psychiatry. 2007;164:1750–6. doi: 10.1176/appi.ajp.2007.07050252.

23. Purdue Pharma L.P. (2008) NDA 22-272 Reformulated OxyContin(R), Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee

24.Zaami S, Marinelli E and Varì MR (2020) New Trends of Substance Abuse During COVID-19 Pandemic: An International Perspective. Front. Psychiatry 11:700. doi: 10.3389/fpsyt.2020.00700

25. Paulozzi LJ. Vital signs: overdoses of prescription opioid pain relievers – United States, 1999–2008. MMWR Morb Mortal Wkly Rep. 2011;**60**:1487–1492.

26. Florence CS, Zhou C, Luo F, et al. The economic burden of prescription opioid overdose, abuse, and dependence in the United States, 2013. Med. Care. 2016;**54**:901–906.

27. Hall AJLJ, Toblin RL, Kaplan JA, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. J Am Med Assoc. 2008;**300**:2613–2620.

28. Binswanger IA, Glanz JM. Pharmaceutical opioids in the home and youth: implications for adult medical practice. Subst Abus. 2015;**36**:141–143.

29. Blackhall LJ, Alfson ED, Barclay JS. Screening for substance abuse and diversion in Virginia hospices. J Palliat Med. 2013;**16**:237–242.

30. Gasior M, Bond M, Malamut R. Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations. Postgrad Med. 2016;**128**:85–96.

31. Green JL, Bucher Bartelson B, Le Lait MC, et al. Medical outcomes associated with prescription opioid abuse via oral and non-oral routes of administration. Drug Alcohol Depend. 2017;**175**:140–145.

32. Budman SH, Grimes Serrano JM, Butler SF. Can abuse deterrent formulations make a difference? Expectation and speculation. Harm Reduct J. 2009;**6**:8.

33. Lankenau SE, Teti M, Silva K, et al. Initiation into prescription opioid misuse amongst young injection drug users. Int J Drug Policy. 2012;**23**:37–44.

34. Yewell J, Haydon R, Archer S, et al. Complications of intranasal prescription narcotic abuse. Ann Otol Rhinol Laryngol. 2002;**111**:174–177

35. Department US. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research Abuse-deterrent opioids – evaluation and labeling: guidance for industry. from: https://www.fda.gov/downloads/Drugs/Guidances/UCM334743.pdf.

36. Hale ME, Moe D, Bond M, et al. Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain. Pain Manag. 2016;**6**:497–508.

37. Harris SC, Perrino PJ, Smith I, et al. Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users. J Clin Pharmacol. 2014;**54**:468–477.

38. Dart RC, Surratt HL, Cicero TJ, et al. Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med. 2015;**372**:241–248.

39. Sellers EM, Perrino PJ, Colucci SV, et al. Attractiveness of reformulated OxyContin® tablets: assessing comparative preferences and tampering potential. J Psychopharmacol. 2013;**27**:808–816.

24. Hysingla™ ER. (hydrocodone bitartrate) extended-release tablets [package insert] Stamford, CT: Purdue Pharma L.P.; 2014.

40. Harris SC, Cipriano A, Colucci SV, et al. Oral abuse potential, pharmacokinetics, and safety of once-daily, single-entity, extended-release hydrocodone (HYD) in recreational opioid users. Pain Med. 2017;**18**:1278–1291.

41. Harris SC, Cipriano A, Colucci SV, et al. Intranasal abuse potential, pharmacokinetics, and safety of once-daily, single-entity, extended-release hydrocodone (HYD) in recreational opioid users. Pain Med. 2016;**17**:820–831.

42. Dart, R. C., Iwanicki, J. L., Dasgupta, N., Cicero, T. J., & Schnoll, S. H. (2017). Do abuse deterrent opioid formulations work?. Journal of opioid management, 13(6), 365-378.

43. PhA (2014) Statement from Ralph G. Neas, president and CEO, GPhA on FDA decision on abuse-deterrent formulations of OxyContin. Available at: http://www.gphaonline.org/gpha-media/press/statement-from-ralph-g-neas-president-and-ceo-gpha-on-fda-decision-on-abuse-deterrent-formulations-of-oxycontin

44. Palekar S, Kumar Nukala P, Vartak R, Patel K. Abuse deterrent immediate release film technology (ADRIFT): A novel bilayer film technology for limiting intentional drug abuse. Int J Pharm. 2020 Nov 30;590:119944. doi: 10.1016/j.ijpharm.2020.119944.

45. Ong JJ, Awad A, Martorana A, Gaisford S, Stoyanov E, Basit AW, Goyanes A. 3D printed opioid medicines with alcohol-resistant and abuse-deterrent properties. Int J Pharm. 2020 Apr 15;579:119169. doi: 10.1016/j.ijpharm.2020.119169.

46. Freeman, P., Brown, J., Dasgupta, N., Nocera, M., & Slavova, S. (2020). Prescriber Survey - Methodological Advances in Evaluating Abuse-deterrent Opioid Analgesics. https://doi.org/10.17615/q7v8-s976

47. Simon, K., Worthy, S. L., Barnes, M. C., & Tarbell, B. (2015). Abuse-deterrent formulations: transitioning the pharmaceutical market to improve public health and safety. Therapeutic Advances in Drug Safety, 67–79. https://doi.org/10.1177/2042098615569726

48. Coplan, P., Kale, H., Sandstrom, L., Landau, C., Chilcoat, H. (2013) Changes in oxycodone and heroin exposures in the national poison data system after introduction of extended-release Oxycodone with abuse-deterrent characteristics. Pharmacoepidemiol Drug Saf 22: 1274–1282

49. FDA (2013b) FDA approves abuse-deterrent labeling for reformulatedOxyContin. http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm348252.htm

50. Mastropietro DJ, Omidian H (2012) Current approaches in tamper-resistant and abuse-deterrent formulations. Drug Dev Ind Pharm